Launch of Buyback Programme

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has launched a share buyback programme of up to US $250 million, excluding stamp duty and expenses, to be completed by 23 September 2026. This initiative, reflecting strong cash generation and balance sheet strength, will be executed in two equal tranches of US $125 million, managed by Citigroup Global Markets Limited and J.P. Morgan Securities plc respectively, with the first tranche commencing immediately and concluding by 9 June 2026. The buyback aims to reduce share capital and is subject to shareholder approval at the 2026 Annual General Meeting for any continuation beyond that date.

Disclaimer*

UK 100

Latest directors dealings